SMS Lifesciences India Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more
SMS Lifesciences India Limited (SMSLIFE) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.71 Billion INR
Based on the latest financial reports, SMS Lifesciences India Limited (SMSLIFE) has total liabilities worth ₹1.71 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SMS Lifesciences India Limited - Total Liabilities Trend (2016–2025)
This chart illustrates how SMS Lifesciences India Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SMS Lifesciences India Limited Competitors by Total Liabilities
The table below lists competitors of SMS Lifesciences India Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moadata Co. Ltd.
KQ:288980
|
Korea | ₩57.70 Billion |
|
PT Surya Esa Perkasa Tbk
STU:71S
|
Germany | €91.05 Million |
|
Swiftmerge Acquisition Corp
NASDAQ:IVCP
|
USA | $17.85 Million |
|
TGLT S.A
PINK:TGLTY
|
USA | $147.93 Billion |
|
Wenzhou Kangning Hospital Co. Ltd
F:4WK
|
Germany | €1.69 Billion |
|
Lotte Chemical Titan Tbk PT
JK:FPNI
|
Indonesia | Rp980.62 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down SMS Lifesciences India Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SMS Lifesciences India Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SMS Lifesciences India Limited (2016–2025)
The table below shows the annual total liabilities of SMS Lifesciences India Limited from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.78 Billion | -9.62% |
| 2024-03-31 | ₹1.97 Billion | +13.57% |
| 2023-03-31 | ₹1.73 Billion | -9.62% |
| 2022-03-31 | ₹1.92 Billion | +10.83% |
| 2021-03-31 | ₹1.73 Billion | +26.25% |
| 2020-03-31 | ₹1.37 Billion | -16.21% |
| 2019-03-31 | ₹1.64 Billion | +85.41% |
| 2018-03-31 | ₹882.47 Million | -8.06% |
| 2017-03-31 | ₹959.82 Million | -7.01% |
| 2016-03-31 | ₹1.03 Billion | -- |